HCPCS code J0894: Decitabine injection, per 1 mg2026 Medicare rate & RVUs in Texas
Decitabine injection is a 1 mg drug unit reported for intravenous antineoplastic treatment, commonly in regimens for myelodysplastic syndromes and acute myeloid leukemia.
CMS doesn’t publish an office rate for J0894 in Texas.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J0894 covers
Decitabine is an antineoplastic drug given by intravenous infusion. Oncology practices and hospital-based cancer services commonly administer it in treatment regimens for myelodysplastic syndromes and for some patients with acute myeloid leukemia. This HCPCS code identifies the drug, not the infusion service; report the administration service separately when applicable.
Each unit represents 1 mg of decitabine, so a 20 mg administered dose corresponds to 20 units. CMS assigns status E, excluding the code from the physician fee schedule; when Medicare covers the drug, payment is through another method. HCPCS pricing classifies it as a Part B drug, generally priced from CMS quarterly Average Sales Price files when covered. Coverage is left to the Medicare contractor's judgment.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J0894 pays more and less in Texas
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
8 of 8 payment localities
| Payment locality | Office | Facility |
|---|---|---|
| Austin, TX | Unavailable | Unavailable |
| Beaumont, TX | Unavailable | Unavailable |
| Brazoria, TX | Unavailable | Unavailable |
| Dallas, TX | Unavailable | Unavailable |
| Fort Worth, TX | Unavailable | Unavailable |
| Galveston, TX | Unavailable | Unavailable |
| Houston, TX | Unavailable | Unavailable |
| Rest of Texas | Unavailable | Unavailable |
How the J0894 rate is calculated
Each of J0894’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J0894
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J0894
J0894 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J0894
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J0894 isn’t priced in this setting.
J0894 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J0893Decitabine injectionSun Pharma product, per 1 mg
- J0893 identifies a Sun Pharma decitabine product. J0894 is the decitabine code without that product-specific designation; select based on the product furnished.
- J9025Azacitidine injectionPer 1 mg
- J9025 is azacitidine, not decitabine. Use J0894 for decitabine and J9025 when azacitidine is administered.
- J0896Luspatercept injectionPer 0.25 mg
- J0896 identifies luspatercept, used for anemia in selected patients with MDS. It is a different drug and is not the decitabine antineoplastic drug unit.
J0894 billing questions
How does J0894 differ from J0893?
Both codes identify decitabine, but J0893 is the product-specific code for a Sun Pharma product. Select the code that matches the product furnished.
How many units should be reported?
One unit represents 1 mg of decitabine. For example, a 20 mg administered dose equals 20 units.
Does J0894 include the infusion administration?
No. J0894 identifies the drug. Report an applicable chemotherapy infusion administration service separately when performed and reportable.
How does Medicare treat J0894?
CMS excludes it from the physician fee schedule with status E. When covered, it is a Part B drug generally priced using CMS quarterly ASP files, and coverage is left to the Medicare contractor's judgment.
Is J0894 interchangeable with azacitidine coding?
No. J0894 identifies decitabine, while J9025 identifies azacitidine. Choose the code for the drug actually administered.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J0894 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist